Charter

February 24, 2023

A Public Private Partnership

CO-HOSTED BY

Moffitt Cancer Center

DiME Digital Medicine Society
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview</td>
<td>3</td>
</tr>
<tr>
<td>Vision</td>
<td>3</td>
</tr>
<tr>
<td>Mission</td>
<td>3</td>
</tr>
<tr>
<td>Goal</td>
<td>3</td>
</tr>
<tr>
<td>Participation and Governance</td>
<td>5</td>
</tr>
<tr>
<td>About the Digital Medicine Society</td>
<td>6</td>
</tr>
<tr>
<td>About Moffitt Cancer Center</td>
<td>6</td>
</tr>
<tr>
<td>Charter Signatories</td>
<td>7</td>
</tr>
</tbody>
</table>
Overview

In early 2022, President Biden reignited the Cancer Moonshot, setting new national goals to cut the death rate from cancer by at least 50% over the next 25 years and improve the experience of people and their families living with and surviving cancer. In its first year, the reignited Cancer Moonshot announced over 25 new programs, policies, and resources in pursuit of these goals.

In February 2023, to mark the one-year anniversary of the new national goals, the Cancer Cabinet – the expert and interagency body responsible for setting the Cancer Moonshot agenda across government agencies – announced three new actions, including the establishment of CancerX - a public-private partnership (PPP) to act as a national accelerator to boost innovation in the fight against cancer.

Vision

To harness the power of innovation to reduce the burden of cancer for all people.

Mission

To unite a diverse and inclusive community of stakeholders to rapidly develop and equitably deploy innovative solutions that can prevent and cure cancer.

Goal

The goal of this PPP is to convene the many stakeholders necessary to create, foster, accelerate, and scale the impact of a community of innovators dedicated to reducing the burden of cancer for all people with unwavering urgency and uncompromising equity.

Answering the call of the White House, CancerX will ignite innovation in pursuit of the promise of a life without cancer through an integrated, three-pronged approach that will generate outsized impact by establishing best practices, building capacity, and demonstrating the impact of innovation on the lives of every person on a cancer journey. Together, we can triumph over cancer and transform the lives of millions.

Figure 1: The initial structure of CancerX
This structure will be built out over the first year of CancerX. The first pre-competitive evidence generation project will be publicly announced on March 28, 2023 in tandem with the announcement of the hosts and founding partners of CancerX. The inaugural accelerator cohort will be announced in October 2023 and the first demonstration project will launch in April 2024.

Figure 2: The timeline of activities in Year 1 of CancerX

- **Public announcement & initiative kick-off**: Mar 28
- **Present and host initiative meeting at ASCO**: June 2-6
- **Announce accelerator at HLTH and announce inaugural cohort, mentors, and industry partners**: Oct 8-11
- **Launch demonstration project**: April

- **Apr-Jun**: Build out inaugural membership & Steering Committee
- **Jul-Oct**: Build out accelerator and recruit inaugural cohort
- **Mar-Apr**: Scope, secure implementation partners and funding for first demonstration project
- **Oct**: Run accelerator
- **Mar**: Conduct inaugural project initiative; scope and launch at least one further initiative
Participation and Governance

The PPP is open to all those working in the field who share our vision and are committed to working collaboratively to achieve it.

Member organizations will include the Office for the National Coordinator for Health Information Technology (ONC), Office of the Assistant Secretary for Health (OASH), and other government agencies and sub-agencies alongside a diverse range of industry members, academic centers, and at least two patient advocacy organizations at all times.

A steering committee of 12 individual representatives from member organizations will serve as equals to set the priorities and practices of the PPP in pursuit of the mission. The CancerX Steering Committee will be named by the hosts and founding partners for the inaugural one year term. Subsequently, Steering Committee members will be elected by the CancerX membership for a one year term. The Steering Committee will meet by video-conference quarterly (monthly to start).

Individual relationships between CancerX and member organizations will be governed by individual member agreements and a standardized onboarding process. To maintain their membership, organizations must adhere to the core values of both DiMe and Moffitt, actively participate in at least one CancerX activity annually.

All decisions made by the PPP are supported democratically through a simple majority vote of the Steering Committee, with dispute adjudication exercised before the full membership. In case of a tie, the Steering Committee Chair may cast an additional vote in support of pursuing initiatives that harness the power of innovation to reduce the burden of cancer for all people.

The Digital Medicine Society (DiMe) and Moffitt Cancer Center serve as the hosts of CancerX and are responsible for:

- Providing general oversight of CancerX
- Administrative and operational support
- Financial oversight
- Promoting an open, diverse, and inclusive membership and community
- Ensuring compliance of CancerX activities with DiMe and Moffitt's charitable missions
A representative from Moffitt Cancer Center will serve as the inaugural Chair of the CancerX Steering Committee for two years. Thereafter, the term of the Chairing Steering Committee organization is one year and Chairs must have served at least one year on the Steering Committee as an ordinary member and must remain on the Steering Committee for at least one year following the end of their term.

Organizations may also contribute to the vision and mission of CancerX without joining as members. Specifically, through the support of and direct participation in research activities, the accelerator, and demonstration projects as they may align with their own interests and priorities. These contributions will be governed by individual agreements between CancerX and the participating organizations.

About the Digital Medicine Society

Founded in 2019, the Digital Medicine Society (DiMe) is the professional home for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health.

DiMe is a 501(c)(3) non-profit organization dedicated to advancing the ethical, effective, equitable, and safe use of digital technologies to redefine healthcare and improve lives. We do this by serving professionals at the intersection of the global healthcare and technology communities, supporting them in developing digital medicine through interdisciplinary collaboration, research, teaching, and the promotion of best practices.

For more information about DiMe and to view our work please visit dimesociety.org.

About Moffitt Cancer Center

Moffitt Cancer Center is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. Through superior patient care, groundbreaking research and community-focused screening and prevention, we are working to decrease cancer deaths and reach more patients. We’re forging a digital-driven future to wholly reimagine how we tackle cancer. And we’re creating an epicenter for innovation, discovery and one day, cures.
Moffitt is a nonprofit organization and one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers in the nation. Visit [Moffitt.org](http://Moffitt.org) for more information.

**Charter Signatories**

<table>
<thead>
<tr>
<th>Community Member</th>
<th>Digital Medicine Society (DiMe)</th>
<th>Moffitt Cancer Center</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>By:</td>
<td>By:</td>
</tr>
<tr>
<td>Name:</td>
<td>Name: Jennifer C. Goldsack</td>
<td>Name: Santosh S. Mohan</td>
</tr>
<tr>
<td>Title:</td>
<td>Title: CEO</td>
<td>Title: Vice President, Digital Innovation</td>
</tr>
<tr>
<td>Address:</td>
<td>Address: 90 Canal St., 4th Floor</td>
<td>Address: 12902 USF Magnolia Drive, Tampa, FL 33612</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:contact@dimesociety.org">contact@dimesociety.org</a></td>
<td><a href="mailto:digital@moffitt.org">digital@moffitt.org</a></td>
</tr>
<tr>
<td></td>
<td>+1-765-234-3463</td>
<td>+1-813-745-0111</td>
</tr>
<tr>
<td>Date:</td>
<td>Date:</td>
<td>Date:</td>
</tr>
</tbody>
</table>